Fisher Asset Management LLC decreased its stake in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 26.3% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 24,465 shares of the biotechnology company’s stock after selling 8,722 shares during the period. Fisher Asset Management LLC’s holdings in Sarepta Therapeutics were worth $3,951,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Clarus Wealth Advisors purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth about $124,000. First Quadrant L P CA bought a new position in Sarepta Therapeutics in the 3rd quarter worth about $130,000. Rockefeller Capital Management L.P. bought a new position in Sarepta Therapeutics in the 2nd quarter worth about $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Sarepta Therapeutics in the 2nd quarter worth about $185,000. Finally, Keybank National Association OH bought a new position in Sarepta Therapeutics in the 2nd quarter worth about $206,000. 89.57% of the stock is currently owned by institutional investors and hedge funds.
Shares of Sarepta Therapeutics stock opened at $133.76 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 9.89 and a current ratio of 10.88. The stock has a market cap of $8.13 billion, a PE ratio of -81.56 and a beta of 1.16. Sarepta Therapeutics Inc has a 12 month low of $47.25 and a 12 month high of $176.50.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, October 24th. The biotechnology company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.29). The firm had revenue of $78.49 million for the quarter, compared to the consensus estimate of $78.84 million. Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 22.76%. Research analysts forecast that Sarepta Therapeutics Inc will post -3.99 EPS for the current year.
In related news, CEO Douglas S. Ingram purchased 16,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, August 15th. The shares were acquired at an average cost of $125.26 per share, for a total transaction of $2,004,160.00. Following the transaction, the chief executive officer now directly owns 399,250 shares in the company, valued at $50,010,055. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sandesh Mahatme sold 107,524 shares of the firm’s stock in a transaction that occurred on Wednesday, October 24th. The stock was sold at an average price of $127.74, for a total value of $13,735,115.76. Following the transaction, the chief financial officer now owns 48,381 shares in the company, valued at $6,180,188.94. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.
A number of equities analysts have weighed in on the company. Piper Jaffray Companies decreased their target price on Sarepta Therapeutics from $189.00 to $168.00 and set an “overweight” rating on the stock in a research note on Friday, October 26th. BidaskClub upgraded Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, October 18th. Zacks Investment Research upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, July 6th. HC Wainwright set a $267.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, July 18th. Finally, BTIG Research set a $190.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Monday, September 24th. Three analysts have rated the stock with a hold rating, twenty-four have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $168.37.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Read More: Risk Tolerance
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.